Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
+$0.06 today
- Market cap
- $193.57M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
Volume 0.43M
Average 1.03M
IKT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Inhibikase Therapeutics, Inc.NASDAQ: IKT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $10.84M rose 3.1% year over year, behind the +20.6% change in trailing-twelve-month research & development. Sequentially, it rose 70.5% from the prior quarter. Over 3 fiscal years it compounded at +35.3% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +3.1% toward the trailing-twelve-month pace of +20.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 29.79M USD
- Year-over-year change
- +73.1%
- 4-year CAGR
- +27.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.79M | +73.1% |
| FY2024 | 2024-12-31 | 17.21M | +26.4% |
| FY2023 | 2023-12-31 | 13.62M | +13.2% |
| FY2022 | 2022-12-31 | 12.03M | +6.0% |
| FY2021 | 2021-12-31 | 11.36M | — |
Research & Development vs competitors
How IKT compares with its peers on the latest reported figures
- IKT's LTM Mar 2026 research & development of $30.12M is the 4th highest of the 8 companies compared; the peer median is $15.76M.
- Its year-over-year change of +20.6% is the 5th highest of 7, against a peer median of +33.3%.
- Over three fiscal years its annual growth of +35.3% compares with a peer median of +7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $38.53M | -58.1% | — | 31.1% | |
| LTM Mar 2026 | $32.45M | -22.6% | +7.0% | — | |
| LTM Mar 2026 | $32.14M | +45.7% | -7.4% | 428.8% | |
| LTM Mar 2026 | $30.12M | +20.6% | +35.3% | — | |
| LTM Mar 2026 | $15.76M | +21.0% | +38.5% | — | |
| LTM Mar 2026 | $7.12M | +45.6% | +1.3% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $4.25M | +96.3% | +120.0% | — |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $365.75K | — | — | — |
| Peer median (excluding IKT) | $15.76M | +33.3% | +7.0% | 230.0% | |
Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.1M | 123.44K | 260.5K | 0 | 0 |
| Cost of Revenue | 11.36M | 6.72K | 13.62M | 26.27K | 0 |
| Gross Profit | (8.26M) | 116.72K | (13.36M) | (26.27K) | 0 |
| Gross Margin | -266.4% | 94.6% | -5127.8% | — | — |
| Research & Development | 11.36M | 12.03M | 13.62M | 17.21M | 29.79M |
| Selling, General & Admin | 0 | 6.21M | 6.73M | 11.38M | 23.56M |
| Operating Expenses | 6.51M | 18.25M | 6.73M | 28.56M | 51.97M |
| Depreciation & Amortization | 14.77M | 6.72K | 177.4K | 26.27K | 60.5K |
| EBITDA | 0 | (18.05M) | (18.85M) | (27.49M) | (53.29M) |
| EBITDA Margin | 0.0% | -14620.4% | -7236.7% | — | — |
| Operating Income | (14.77M) | (18.13M) | (20.09M) | (28.59M) | (51.97M) |
| Operating Margin | -476.2% | -14686.2% | -7712.0% | — | — |
| Interest Income | 19.92K | 74.45K | 1.06M | 1.07M | 3.72M |
| Interest Expense | 19.92K | 74.45K | 0 | 0 | 0 |
| Other Income / Expenses | (19.92K) | 74.45K | 1.06M | 1.07M | 3.72M |
| Income Before Tax | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Pre-Tax Margin | -476.9% | -14625.9% | -7304.8% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Net Margin | -476.9% | -14625.9% | -7304.8% | — | — |
| EPS (Basic) | (4.88) | (4.26) | (3.57) | (1.16) | (0.49) |
| EPS (Diluted) | (4.88) | (4.26) | (3.57) | (1.16) | (0.49) |
| Weighted Avg Shares | 3.03M | 4.2M | 5.33M | 69.36M | 98.31M |
| Weighted Avg Shares (Diluted) | 3.03M | 4.2M | 5.33M | 69.36M | 98.31M |
Inhibikase Therapeutics, Inc.
NASDAQ:IKT
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.